Ruifu Chemical Supply Palbociclib Related Intermediates:
Palbociclib CAS 571190-30-2
5-Bromo-2,4-Dichloropyrimidine CAS 36082-50-5
5-Bromo-2-Chloro-N-Cyclopentylpyrimidin-4-Amine CAS 733039-20-8
tert-Butyl 4-(6-Nitropyridin-3-yl)piperazine-1-Carboxylate CAS 571189-16-7
tert-Butyl 4-(6-Amino-3-Pyridyl)piperazine-1-Carboxylate CAS 571188-59-5
6-Bromo-2-Chloro-8-Cyclopentyl-5-Methylpyrido-[2,3-d]pyrimidin-7(8H)-one CAS 1016636-76-2
2-Chloro-8-Cyclopentyl-5-Methyl-8H-Pyrido[2,3-d]pyrimidin-7-one CAS 1013916-37-4
| Chemical Name | Palbociclib |
| Synonyms | PD-0332991; Otava-Bb 1115529; Ibrance |
| CAS Number | 571190-30-2 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C24H29N7O2 |
| Molecular Weight | 447.54 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White or Off-White Powder |
| 1H NMR Spectrum | Consistent With Structure |
| HPLC | Consistent With Structure |
| Related Substances | |
| Individual Impurity | <0.50% |
| Total Impurities | <1.00% |
| Loss on Drying | <0.50% |
| Residue on Ignition | <0.10% |
| Heavy Metals | <10ppm |
| Purity / Analysis Method | >99.5% (HPLC) |
| Test Standard | Enterprise Standard |
| Usage | API, In the Treatment of Breast Cancer |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture
Palbociclib (CAS: 571190-30-2) is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation. Palbociclib is the first representative of the new drug class of cyclin-dependent kinase inhibitors. This effect limits cell proliferation (cell growth and division). It is used as an antineoplastic agent in advanced or metastatic breast cancer.